Avidity Biosciences (RNA) Price & Analysis

Compare

1,051 Followers

RNA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$21.51 - $56.00

Previous CloseN/A

Volume185.29K

Average Volume (3M)3.32M

Market Cap

$6.05B

Enterprise Value$2.50B

Total Cash (Recent Filing)$1.18B

Total Debt (Recent Filing)$5.13M

Price to Earnings (P/E)―

Beta1.88

Next Earnings

Nov 11, 2025

EPS Estimate

-1.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.21

Shares Outstanding128,653,340

10 Day Avg. Volume2,470,906

30 Day Avg. Volume3,324,516

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.41

Enterprise Value/Revenue233.32

Enterprise Value/Gross Profit252.47

Enterprise Value/Ebitda-4.82

Forecast

1Y Price Target

$67.82

Price Target Upside44.14% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering18

Bulls Say, Bears Say

Bulls Say

Manufacturing AgreementsRNA entered into a 7-year commercial manufacturing agreement with Lonza, supporting its global approval strategy and ensuring future manufacturing requirements are met.

Regulatory ProgressRNA's alignment with the FDA on accelerated and full approval pathways for del-brax in FSHD is a positive development.

Strategic InterestThe attention of a potential strategic match has sent the stock up considerably, indicating strong market interest.

Bears Say

Earnings MissNet loss per share was ($1.21) compared to a consensus of ($0.96), showing weaker than expected financial results.

Financial PerformanceRNA reported a 2Q25 net loss of $157.3M with a significant increase in R&D expenses, indicating weaker than expected financial performance.

Operational CostsRNA reported a significant increase in R&D expenses, impacting its net loss and financial performance.

Avidity Biosciences News

Sector Spotlight: Trump administration seeks hometown discount from Big Pharma

Welcome to the latest “Sector Spotlight,” where The Fly looks at a new industry every week and highlights...

20d ago

AZN

BMY

Avidity Biosciences price target raised to $75 from $70 at Wells Fargo

Wells Fargo raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $70 and keeps an...

21d ago

RNA

Avidity Biosciences price target raised to $62 from $59 at Barclays

Barclays raised the firm’s price target on Avidity Biosciences (RNA) to $62 from $59 and keeps an Overweight...

21d ago

RNA

Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c)

Reports Q2 revenue $3.8M, consensus $1.61M. Expects that its cash, cash equivalents and marketable securities as of June...

21d ago

RNA

Disney reports Q3 beat and NFL deal, Uber authorizes $20B buyback: Morning Buzz

The major averages were higher near noon, led by the Nasdaq, as investors reacted to another heavy dose...

22d ago

Avidity up over 20% to $46.05 after FT report of buyout interest

11:44 EDT Avidity up over 20% to $46.05 after FT report of buyout interest Published first on TheFly...

22d ago

RNA

Novo Nordisk made takeover approach to Avidity Biosciences, FT reports

11:16 EDT Novo Nordisk (NVO) made takeover approach to Avidity Biosciences (RNA), FT reports Published first on TheFly...

22d ago

NVO

RNA

Avidity jumps 3% to $39.47 after FT report of takeover approach

11:17 EDT Avidity jumps 3% to $39.47 after FT report of takeover approach Published first on TheFly –...

22d ago

RNA

Avidity Biosciences trading resumes

11:20 EDT Avidity Biosciences (RNA) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

22d ago

RNA

Novartis makes takeover approach for Avidity Biosciences, FT reports

Novartis (NVS) has made a takeover offer for Avidity Biosciences (RNA), which has a market value of $4.3B,...

22d ago

NVS

RNA

Avidity Biosciences Advances RNA Therapeutics with Strong Q2

Avidity Biosciences Inc ( ($RNA) ) has released its Q2 earnings. Here is a breakdown of the information...

13d ago

RNA

Promising Potential of Avidity Biosciences: Buy Rating Affirmed by Ananda Ghosh

Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on Avidity Biosciences. The associated price target...

18d ago

RNA

Avidity Biosciences: Strong Buy Rating Backed by Promising Clinical Outcomes and Robust Financial Position

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Avidity Biosciences, retaining the price target of...

20d ago

RNA

Avidity Biosciences: Promising Pipeline and Strong Financials Justify Buy Rating

Needham analyst Joseph Stringer has maintained their bullish stance on RNA stock, giving a Buy rating today. Joseph...

21d ago

RNA

RNA FAQ

What was Avidity Biosciences Inc’s price range in the past 12 months?

Avidity Biosciences Inc lowest stock price was $21.51 and its highest was $56.00 in the past 12 months.

What is Avidity Biosciences Inc’s market cap?

Avidity Biosciences Inc’s market cap is $6.05B.

When is Avidity Biosciences Inc’s upcoming earnings report date?

Avidity Biosciences Inc’s upcoming earnings report date is Nov 11, 2025 which is in 75 days.

How were Avidity Biosciences Inc’s earnings last quarter?

Avidity Biosciences Inc released its earnings results on Aug 07, 2025. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$0.958 by -$0.252.

Is Avidity Biosciences Inc overvalued?

According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avidity Biosciences Inc pay dividends?

Avidity Biosciences Inc does not currently pay dividends.

What is Avidity Biosciences Inc’s EPS estimate?

Avidity Biosciences Inc’s EPS estimate is -1.14.

How many shares outstanding does Avidity Biosciences Inc have?

Avidity Biosciences Inc has 128,653,340 shares outstanding.

What happened to Avidity Biosciences Inc’s price movement after its last earnings report?

Avidity Biosciences Inc reported an EPS of -$1.21 in its last earnings report, missing expectations of -$0.958. Following the earnings report the stock price went down -2.588%.

Which hedge fund is a major shareholder of Avidity Biosciences Inc?

Currently, no hedge funds are holding shares in RNA

Avidity Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.76%

Trailing 12-Months

Asset Growth

1.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avidity Biosciences Inc

Avidity Biosciences is a biopharmaceutical company operating in the healthcare sector, primarily focused on developing therapies using their proprietary Antibody Oligonucleotide Conjugates (AOCs) platform. AOCs are designed to treat a range of serious diseases by delivering synthetic oligonucleotides directly to target tissues. The company is dedicated to advancing innovative treatments for genetic diseases, leveraging its expertise in oligonucleotide therapies to improve patient outcomes.

Avidity Biosciences (RNA) Earnings & Revenues

Historic Earnings Reports

RNA Stock 12 Month Forecast

Average Price Target

$67.82

▲(44.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","43":"$43","61":"$61","79":"$79","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$52.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,43,61,79,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,40.541538461538465,45.16307692307693,49.784615384615385,54.40615384615385,59.02769230769231,63.64923076923077,68.27076923076923,72.8923076923077,77.51384615384616,82.13538461538462,86.75692307692307,91.37846153846155,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,38.37384615384615,40.82769230769231,43.28153846153846,45.73538461538462,48.18923076923077,50.64307692307692,53.096923076923076,55.55076923076923,58.00461538461538,60.458461538461535,62.912307692307685,65.36615384615384,{"y":67.82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.92,37.15692307692308,38.393846153846155,39.63076923076923,40.86769230769231,42.104615384615386,43.34153846153846,44.57846153846154,45.815384615384616,47.05230769230769,48.28923076923077,49.526153846153846,50.76307692307692,{"y":52,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >